SCHEMBL7099515

SCHEMBL7099515

Cn1c(=O)n(C/C=C/c2ccncc2)c(=O)c2cc(C(=O)O)ccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBXAS1 P24557 3/20 0.43
MMP13 P45452 1/20 0.43
SLC22A8 Q8TCC7 1/20 0.43
PARG Q86W56 2/20 0.42
KDM4E B2RXH2 2/20 0.41
TP53 P04637 6/20 0.41
LMNA P02545 3/20 0.41
MAPT P10636 3/20 0.41
POLB P06746 1/20 0.41
GAA P10253 2/20 0.38
ALDH1A1 P00352 2/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 2/20 0.37
ALOX15 P16050 1/20 0.37
MAPK1 P28482 1/20 0.37
HSD17B10 Q99714 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
USP2 O75604 1/20 0.37
PKM P14618 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7099516 1.00 TBXAS1 (0.43) TBXAS1MMP13SLC22A8PARGKDM4E
SCHEMBL6242777 0.90 MMP13 (0.49) MMP13SLC22A8PARGKDM4ETP53
SCHEMBL6242785 0.90 MMP13 (0.49) MMP13SLC22A8PARGKDM4ETP53
SCHEMBL7106533 0.81 MMP13 (0.59) TBXAS1MMP13SLC22A8PARGKDM4E
SCHEMBL6244546 0.80 ROCK2 (0.47) MMP13KDM4ETP53LMNAMAPT
SCHEMBL7098685 0.80 ROCK2 (0.47) MMP13KDM4ETP53LMNAMAPT
SCHEMBL6510481 0.79 MMP13 (0.48) TBXAS1MMP13SLC22A8PARGKDM4E
SCHEMBL6241073 0.72 MMP13 (0.71) MMP13SLC22A8PARGKDM4EALDH1A1
SCHEMBL6510783 0.72 KDM4E (0.59) TBXAS1MMP13SLC22A8PARGKDM4E
SCHEMBL6513615 0.71 MMP13 (0.58) MMP13SLC22A8KDM4EMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1368324-A1 QUINAZOLINES AS MMP-13 INHIBITORS Warner-Lambert Company LLC (US) 2003-12-10 EP claimed
US-20020193377-A1 Quinazolines as MMP-13 inhibitors ANDRIANJARA CHARLES (FR) 2002-12-19 US claimed
WO-2002064572-A1 QUINAZOLINES AS MMP-13 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193377-A1 Quinazolines as MMP-13 inhibitors MMP13, MMP9, MMP3 TBXAS1 2005/4885MMP13 1/4885SLC22A8 315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.